<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD"><gtr:id>59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD</gtr:id><gtr:name>The Pirbright Institute</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Ash Road</gtr:line1><gtr:line2>Pirbright</gtr:line2><gtr:line4>Woking</gtr:line4><gtr:line5>Surrrey</gtr:line5><gtr:postCode>GU24 0NF</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD"><gtr:id>59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD</gtr:id><gtr:name>The Pirbright Institute</gtr:name><gtr:address><gtr:line1>Ash Road</gtr:line1><gtr:line2>Pirbright</gtr:line2><gtr:line4>Woking</gtr:line4><gtr:line5>Surrrey</gtr:line5><gtr:postCode>GU24 0NF</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/989E7D51-B2C3-4470-999E-30C9AF5A5E4B"><gtr:id>989E7D51-B2C3-4470-999E-30C9AF5A5E4B</gtr:id><gtr:firstName>Bryan</gtr:firstName><gtr:surname>Charleston</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BBS%2FE%2FI%2F00001494"><gtr:id>93A89393-5569-43DC-A1F7-466D4A3B7C5E</gtr:id><gtr:title>Structurally modified master seed viruses to enhance conventional foot-and-mouth disease virus vaccine protection</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>BBS/E/I/00001494</gtr:grantReference><gtr:abstractText>The current FMD vaccines are inactivated whole virus preparations. Despite success in the developed world, two major problems limit their capacity to control infections in developing countries. First, the virus is notoriously unstable, especially for the serotypes O and SAT2. During production the manufacturer has to compensate for this instability, which is expensive and reduces vaccine yield. Also, unstable vaccines are believed to be less immunogenic due to degradation before and after inoculation. In addition, to be effective, FMDV vaccines require frequent booster vaccinations, possibly due to vaccine antigen instability. Secondly, FMDV serotypes can be highly variable, especially serotypes A and SAT2, necessitating frequent development of new vaccine strains. Some viruses have proven very difficult to adapt to cell culture, slowing the manufacturing process, reducing vaccine yield and potentiating the selection of undesired antigenic changes.The main objectives of this proposal are to use reverse genetics to produce and market, on an industrial scale, recombinant FMD viruses with enhanced thermal stability and cell-culture growth. Currently, live recombinant viruses can be recovered and inactivated vaccine produced in the conventional manner. However, the feasibility of applying this technology on an industrial scale has not yet been tested.</gtr:abstractText><gtr:fund><gtr:end>2013-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2010-04-01</gtr:start><gtr:type>EXPENDITURE_PROJECTED</gtr:type><gtr:valuePounds>35100</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>This was a Wellcome Trust funded award</gtr:description><gtr:exploitationPathways>New Welcome trust grant application has been funded</gtr:exploitationPathways><gtr:id>6474A99B-A385-4CC3-8333-2BAAA5349DCB</gtr:id><gtr:outcomeId>56e003d9ef4449.75686570</gtr:outcomeId><gtr:sectors><gtr:sector>Agriculture, Food and Drink,Healthcare</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>684325A8-6DDE-4821-B155-0254A28466DC</gtr:id><gtr:title>Structure-based energetics of protein interfaces guides foot-and-mouth disease virus vaccine design.</gtr:title><gtr:parentPublicationTitle>Nature structural &amp; molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/20e79016261bda0ee71b2fa191e508ed"><gtr:id>20e79016261bda0ee71b2fa191e508ed</gtr:id><gtr:otherNames>Kotecha A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1545-9985</gtr:issn><gtr:outcomeId>56657d33e21782.25231366</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3601C6B-9C2E-4645-B0B6-0C37126518D1</gtr:id><gtr:title>Efficient production of foot-and-mouth disease virus empty capsids in insect cells following down regulation of 3C protease activity.</gtr:title><gtr:parentPublicationTitle>Journal of virological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81fdc957a28d6737e58833c54f96c493"><gtr:id>81fdc957a28d6737e58833c54f96c493</gtr:id><gtr:otherNames>Porta C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0166-0934</gtr:issn><gtr:outcomeId>544a4d39f03420.97209909</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49751981-9716-4C8B-A6CF-8F6E73197EEA</gtr:id><gtr:title>Determining the epitope dominance on the capsid of a serotype SAT2 foot-and-mouth disease virus by mutational analyses.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ccad99e12fc41a8afbefe73b98e70d8d"><gtr:id>ccad99e12fc41a8afbefe73b98e70d8d</gtr:id><gtr:otherNames>Opperman PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>56cc24c9c4b192.43704221</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>056568C8-75B2-46B4-B01B-F88DBE7C6D06</gtr:id><gtr:title>Characterization of epitope-tagged foot-and-mouth disease virus.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b5ec0ebcc691662b7092a6145fd67ae"><gtr:id>5b5ec0ebcc691662b7092a6145fd67ae</gtr:id><gtr:otherNames>Seago J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>544a4d3a280b60.06055822</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B575A7D7-B0E9-4755-9374-23E5A70BEAFF</gtr:id><gtr:title>SAT2 Foot-and-Mouth Disease Virus Structurally Modified for Increased Thermostability.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb6d833e61be5c4ba09683407b39387b"><gtr:id>bb6d833e61be5c4ba09683407b39387b</gtr:id><gtr:otherNames>Scott KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>59147410d3e682.60482266</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>655CB794-9E31-4AE9-BD69-6FA0FF0D327C</gtr:id><gtr:title>Application of the thermofluor PaSTRy technique for improving foot-and-mouth disease virus vaccine formulation.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/20e79016261bda0ee71b2fa191e508ed"><gtr:id>20e79016261bda0ee71b2fa191e508ed</gtr:id><gtr:otherNames>Kotecha A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>58c0568de4d9b6.49514062</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BBS/E/I/00001494</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>